OTC Pharmaceuticals in United Arab Emirates
MarketLine, March 2012, Pages: 35
Introduction
OTC Pharmaceuticals in United Arab Emirates industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2006-10, and forecast to 2015). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the United Arab Emirates otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
-The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria’s, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2010 annual average exchange rates.
-The Emirati OTC pharmaceuticals market generated total revenues of $230.4 million in 2010, representing a compound annual growth rate (CAGR) of 9.2% for the period spanning 2006-2010.
-Analgesics sales proved the most lucrative for the Emirati OTC pharmaceuticals market in 2010, generating total revenues of $49.2 million, equivalent to 21.4% of the market's overall value.
-The performance of the market is forecast to decelerate, with an anticipated CAGR of 6.3% for the five-year period 2010-2015, which is expected to lead the market to a value of $312.1 million by the end of 2015.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the otc pharmaceuticals market in United Arab Emirates
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in United Arab Emirates
Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the United Arab Emirates otc pharmaceuticals market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the United Arab Emirates economy
Key Questions Answered
What was the size of the United Arab Emirates otc pharmaceuticals market by value in 2010?
What will be the size of the United Arab Emirates otc pharmaceuticals market in 2015?
What factors are affecting the strength of competition in the United Arab Emirates otc pharmaceuticals market?
How has the market performed over the last five years?
Who are the top competitiors in United Arab Emirates's otc pharmaceuticals market?
TABLE OF CONTENTS
EXECUTIVE SUMMARY 2
MARKET OVERVIEW 6
Market definition 6
Market analysis 6
MARKET DATA 7
Market value 7
MARKET SEGMENTATION 8
Category segmentation 8
Geography segmentation 10
Market share 11
Market distribution 12
MARKET OUTLOOK 13
Market value forecast 13
FIVE FORCES ANALYSIS 14
Summary 14
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
LEADING COMPANIES 20
Novartis AG 20
Johnson & Johnson 23
GlaxoSmithKline Plc 27
MACROECONOMIC INDICATORS 30
Country Data 30
APPENDIX 32
Methodology 32
Industry associations 33
Related MarketLine research 33
LIST OF TABLES
Table 1: United Arab Emirates OTC pharmaceuticals market value: $ million, 2006–10 7
Table 2: United Arab Emirates OTC pharmaceuticals market category segmentation : % share, by value, 2006 - 2010 8
Table 3: United Arab Emirates OTC pharmaceuticals market category segmentation : $million, by value, 2006 - 2010 8
Table 4: United Arab Emirates OTC pharmaceuticals market geography segmentation, by value, 2010 10
Table 5: United Arab Emirates OTC pharmaceuticals market share: % share, by value, 2010 11
Table 6: United Arab Emirates OTC pharmaceuticals market distribution: % share, by value, 2010 12
Table 7: United Arab Emirates OTC pharmaceuticals market value forecast: $ million, 2010–15 13
Table 8: Novartis AG: key facts 20
Table 9: Novartis AG: key financials ($) 21
Table 10: Novartis AG: key financial ratios 21
Table 11: Johnson & Johnson: key facts 23
Table 12: Johnson & Johnson: key financials ($) 24
Table 13: Johnson & Johnson: key financial ratios 25
Table 14: GlaxoSmithKline Plc: key facts 27
Table 15: GlaxoSmithKline Plc: key financials ($) 28
Table 16: GlaxoSmithKline Plc: key financials (£) 28
Table 17: GlaxoSmithKline Plc: key financial ratios 28
Table 18: United Arab Emirates size of population (million), 2006–10 30
Table 19: United Arab Emirates gdp (constant 2000 prices, $ billion), 2006–10 30
Table 20: United Arab Emirates gdp (current prices, $ billion), 2006–10 30
Table 21: United Arab Emirates inflation, 2006–10 31
Table 22: United Arab Emirates consumer price index (absolute), 2006–10 31
Table 23: United Arab Emirates exchange rate, 2006–10 31
LIST OF FIGURES
Figure 1: United Arab Emirates OTC pharmaceuticals market value: $ million, 2006–10 7
Figure 2: United Arab Emirates OTC pharmaceuticals market category segmentation : $million, by value, 2006 - 2010 9
Figure 3: United Arab Emirates OTC pharmaceuticals market geography segmentation : % share, by value, 2010 10
Figure 4: United Arab Emirates OTC pharmaceuticals market share: % share, by value, 2010 11
Figure 5: United Arab Emirates OTC pharmaceuticals market distribution: % share, by value, 2010 12
Figure 6: United Arab Emirates OTC pharmaceuticals market value forecast: $ million, 2010–15 13
Figure 7: Forces driving competition in the OTC pharmaceuticals market in United Arab Emirates, 2010 14
Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in United Arab Emirates, 2010 15
Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in United Arab Emirates, 2010 16
Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in United Arab Emirates, 2010 17
Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in United Arab Emirates, 2010 18
Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in United Arab Emirates, 2010 19
Figure 13: Novartis AG: revenues & profitability 22
Figure 14: Novartis AG: assets & liabilities 22
Figure 15: Johnson & Johnson: revenues & profitability 25
Figure 16: Johnson & Johnson: assets & liabilities 26
Figure 17: GlaxoSmithKline Plc: revenues & profitability 29
Figure 18: GlaxoSmithKline Plc: assets & liabilities 29
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
